TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)

TWD 10.9

(-3.11%)

Market Cap (In TWD)

7.82 Billion

Revenue (In TWD)

123.13 Million

Net Income (In TWD)

136.73 Million

Avg. Volume

1.3 Million

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
10.8-17.25
PE
-
EPS
-
Beta Value
0.763
ISIN
KYG866171005
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Kuo-Lung Huang
Employee Count
-
Website
https://www.taigenbiotech.com.tw
Ipo Date
2013-08-30
Details
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.